Rockefeller Capital Management’s Pacer BioThreat Strategy ETF VIRS Stock Holding History

Rockefeller Capital Management’s Portfolio VIRS Stock Details VIRS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-1,403	Closed	-$39K	–	4015
2022 Q4	$39K	Buy	+1,403	New	+$38.8K	﹤0.01%	2509

Other funds holding VIRS

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Rockefeller Capital Management's VIRS Position: Q1 2023 in Review

Rockefeller Capital Management sold out of Pacer BioThreat Strategy ETF (VIRS) in Q1 2023, closing a stake of 1,403 shares — an estimated $39K sold.

Rockefeller Capital Management first reported a position in VIRS in Q4 2022 and held it in 1 quarter. The position peaked at $39K in Q4 2022. 4 funds tracked by Wall St. Rank hold VIRS as of Q1 2023.

Rockefeller Capital Management reported no remaining Pacer BioThreat Strategy ETF position as of Q1 2023 after selling out during the quarter.
Rockefeller Capital Management sold 1,403 Pacer BioThreat Strategy ETF shares in Q1 2023, an estimated $39K.
Rockefeller Capital Management first reported a position in Pacer BioThreat Strategy ETF in Q4 2022 and held it in 1 quarter.
Rockefeller Capital Management's Pacer BioThreat Strategy ETF position peaked at $39K in Q4 2022.
4 funds tracked by Wall St. Rank held Pacer BioThreat Strategy ETF as of Q1 2023.

Based on Rockefeller Capital Management's 13F filing for Q1 2023, filed 16 May 2023.